Seaweed-derived drug therapeutically remodels gut microbiome and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression in a mouse model. The drug is undergoing Phase 3 human clinical trials and has just been approved to treat Alzheimer’s in China.